At Week 12 of treatment , ERN/LRPT significantly improved low-density lipoprotein cholesterol , high-density lipoprotein cholesterol ( HDL-C ) , non-high-density lipoprotein cholesterol , triglycerides , and lipoprotein ( a ) , compared with placebo , with equal efficacy in patients above or below median baseline glycemic control .